Just how common is TTS after a second dose of the ChAdOx1 nCov-19 vaccine? - Authors' reply
Lancet
.
2021 Nov 13;398(10313):1801-1802.
doi: 10.1016/S0140-6736(21)02317-5.
Authors
Prakash Bhuyan
1
,
Jennie Medin
2
,
Hugo Gomes da Silva
3
,
Madhavi Yadavalli
4
,
Magnus Nord
5
Affiliations
1
Clinical Development, Late-stage Development, Respiratory and Immunology, BioPharmaceuticals Research and Development, AstraZeneca, Gaithersburg, MD, USA.
2
BioPharmaceuticals Medical, AstraZeneca, Gothenburg SE431 83, Sweden.
3
BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK.
4
Patient Safety, Chief Medical Office, Research and Development, AstraZeneca, Gaithersburg, MD, USA.
5
Patient Safety, Chief Medical Office, Research and Development, AstraZeneca, Gothenburg SE431 83, Sweden. Electronic address: magnus.nord@astrazeneca.com.
PMID:
34774142
DOI:
10.1016/S0140-6736(21)02317-5
No abstract available
Publication types
Letter
Comment
MeSH terms
COVID-19 Vaccines
ChAdOx1 nCoV-19
Humans
Immunization, Secondary
Vaccines*
Substances
COVID-19 Vaccines
Vaccines
ChAdOx1 nCoV-19